Corvus Pharmaceuticals, Inc.
For the period ended Mar 31, 2026. Filed May 7, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 7, 2026
CRVS$11.37+0.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Changes in Stockholders’ Equity
(in thousands, except share data)
| | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · Three Months Ended March 31, 2026 | |||||||||||||||||
| · · · · · · · · · · Accumulated · · · · · · | |||||||||||||||||
| · · · · · · · Additional · · Other · · · · · Total | |||||||||||||||||
| · · Common Stock · · Paid-in · · Comprehensive · · Accumulated · · Stockholders’ | |||||||||||||||||
| · · Shares · · Amount · · Capital · · Loss · · Deficit · · Equity | |||||||||||||||||
| Balance at December 31, 2025 | | 74,696,629 | | $7 | | $474,387 | | $(896) | | $(412,293) | | $61,205 | |||||
| Common stock issued upon exercise of stock options | | 308,017 | | | — | | | 1,339 | | | — | | | — | | | 1,339 |
| Issuance of common stock upon follow-on public offering, net | | 9,085,778 | | | 1 | | | 189,406 | | | — | | | — | | | 189,407 |
| Stock-based compensation expense | | — | | | — | | | 2,650 | | | — | | | — | | | 2,650 |
| Unrealized loss on marketable securities | | — | | | — | | | — | | | (334) | | | — | | | (334) |
| Foreign currency translation adjustment | | — | | | — | | | — | | | 104 | | | — | | | 104 |
| Net loss | | — | | | — | | | — | | | — | | | (13,692) | | | (13,692) |
| Balance at March 31, 2026 | | 84,090,424 | | $8 | | $667,782 | | $(1,126) | | $(425,985) | | $240,679 | |||||
| | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · Three Months Ended March 31, 2025 | |||||||||||||||||
| · · · · · · · · · · Accumulated · · · · · · | |||||||||||||||||
| · · · · · · · Additional · · Other · · · · · Total | |||||||||||||||||
| · · Common Stock · · Paid-in · · Comprehensive · · Accumulated · · Stockholders’ | |||||||||||||||||
| · · Shares · · Amount · · Capital · · Loss · · Deficit · · Equity | |||||||||||||||||
| Balance at December 31, 2024 | | 67,899,779 | | $7 | | $430,859 | | $(1,288) | | $(397,010) | | $32,568 | |||||
| Common stock issued upon exercise of stock options | | 269,682 | | | — | | | 279 | | | — | | | — | | | 279 |
| Stock-based compensation expense | | — | | | — | | | 1,251 | | | — | | | — | | | 1,251 |
| Unrealized loss on marketable securities | | — | | | — | | | — | | | (23) | | | — | | | (23) |
| Foreign currency translation adjustment | | — | | | — | | | — | | | 57 | | | — | | | 57 |
| Net income | | — | | | — | | | — | | | — | | | 15,193 | | | 15,193 |
| Balance at March 31, 2025 | | 68,169,461 | | $7 | | $432,389 | | $(1,254) | | $(381,817) | | $49,325 | |||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.